^
Association details:
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
New
Source:
Excerpt:
Pilocytic astrocytoma, PXA, ganglioglioma if BRAF V600E activation mutation... BRAF/MEK inhibitors...Dabrafenib/trametinib...Vemurafenib/cobimetinib.
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Melanoma)
New
Excerpt:
COTELLIC is a kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.